The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Subscribe To Our Newsletter & Stay Updated
